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PENILAIAN KEPATUHAN  PENGUBATAN, PENGETAHUAN 
DAN KUALITI KEHIDUPAN YANG BERKAITAN KESIHATAN 
DALAM KALANGAN PESAKIT  FIBRILASI ATRIUM YANG 
MENGGUNAKAN WARFARIN DI PULAU PINANG, MALAYSIA 
 
 
ABSTRAK 
Penggunaan terapi antikoagulan  oral (OAC) merupakan suatu amalan 
klinikal yang standard untuk mencegah strok pada pesakit fibrilasi atrium. Di 
Malaysia, tidak banyak kajian dijalankan tentang penilaian pengetahuan, 
ketidakpatuhan dan kualiti hidup dalam kalangan pesakit dengan penggunaan 
warfarin yang kronik dan perkaitan dengan kawalan antikoagulan.  
Projek PhD ini bertujuan mengkaji pengetahuan serta kepatuhan pesakit 
fibrilasi atrium di Pulau Pinang terhadap ubatan antikoagulan oral, menilai corak 
kualiti hidup berkaitan kesihatan (HRQoL), serta mengkaji perkaitan antara variabel 
atau kajian terdahulu dengan kawalan antikoagulan sebagaimana yang diukur melalui 
INR (International Normalized Ratio). Kajian ini turut mengkaji faktor peramal  lain, 
yang berpotensi menjelaskan tentang variasi nilai INR. Suatu model baru 
dibangunkan bagi menjelaskan peramal daripada nilai INR terkawal. 
Kajian rentas-silang ini dijalankan di Klinik Kardiologi di Hospital Pulau 
Pinang dan Hospital Seberang Jaya, di Pulau Pinang. Ujian Pengetahuan 
Antikoagulan Oral (OAK) digunakan untuk mengukur pengetahuan tentang 
antikoagulan, Sebaliknya, untuk mengukur HRQoL, dua instrumen digunakan iaitu, 
Skala Kepuasan Antikoagulan Duke (DASS) dan EuroQoL yang berdimensi-lima 
dan bertahap-tiga (EQ-5D-3L). Kedua-dua OAK dan DASS diterjemah ke dalam 
bahasa Melayu dan diuji sifat psikometriknya. Bagi penilaian kepatuhan, Skala 
Kepatuhan Ubatan Morisky  beritem-lapan (MMAS-8) dan versi Bahasa Melayu 
MMAS-BM telah digunakan. Satu soal selidik yang terdiri daripada sosiodemografi 
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dan ciri-ciri penyakit disediakan dalam dwibahasa (Bahasa Inggeris dan Bahasa 
Melayu)    
Bagi penilaian kawalan INR pesakit, dua kaedah digunakan. 
Pertama, kaedah masa dalam julat terapeutik (TTR), yang dikenali juga 
sebagai kaedah Rosendaal. Kedua, kaedah kestabilan INR yang melibatkan 
bilangan lawatan, dan bacaan INR adalah julat dibahagikan dengan jumlah 
lawatan (INR%).   
Daripada sampel seramai 382 pesakit AF yang memenuhi kriteria 
penyelidikan, 339 pesakit telah melengkapkan soal selidik DASS, EQ-5D dan 
MMAS-8. Namun demikian, hanya 328 pesakit melengkapkan ujian OAK dan 
memasuki analisis akhir. Dalam kalangan semua peserta kajian, min umur ± SD 
adalah  60.4±14.5 tahun. Secara amnya, pengetahuan peserta kajian tentang warfarin 
adalah lemah, iaitu dengan min skor OAK 0.47±0.18, dan hanya 9.5% pesakit 
mencapai kadar lulus 75%.  Mereka kurang–tahu tentang aspek asas warfarin 
(penyesuaian diet, herba, drug dan interaksi alkohol dengan warfarin, pengurusan dos 
dan keberlakuannya, dan interpretasi keputusan INR). Kajian ini menunjukkan suatu 
perkaitan yang positif di antara pengetahuan tentang warfarin dan kawalan 
antikoagulan (TTR dan INR%) (P<0.05). 
Dalam kajian ini, hanya 48.4% (n=164) pesakit dilaporkan mempunyai 
kepatuhan yang tinggi terhadap pengambilan ubatan. Ketidakpatuhan yang tinggi 
dilaporkan oleh pesakit yang lebih muda, mempunyai tahap pendidikan yang rendah, 
skor pengetahuan yang rendah, menjalani tempoh terapi warfarin yang lebih lama, 
dan mengambil ubatan yang kurang. Namun demikian, hanya umur, skor 
pengetahuan ubatan, dan AF dengan komorbiditi merupakan peramal kepatuhan 
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dalam analisis multivariat. Dalam kajian ini, terdapat korelasi yang lemah di antara 
kepatuhan pesakit dan kawalan antikoagulan (TTR atau INR%). 
Penilaian QoL pesakit AF menunjukkan suatu persepsi QoL positif dengan 
purata skor  DASS  adalah 70.8 (±19.8), dan purata skor EQ-5D adalah 79.8% 
(±26.3), menunjukkan satu penilaian yang lemah dalam domain mobiliti dan sakit. 
Kajian ini menonjolkan perkaitan yang signifikan di antara  tahap kawalan 
antikoagulan dan impaknya terhadap QoL (P<0.05). 
  Daripada semua faktor yang dikaji, analisis multivariat menunjukkan 
bahawa hanya tempoh penggunaan warfarin (2-5 tahun) yang lebih panjang dan 
pengetahuan yang tinggi tentang warfarin (skor OAK ≥75%) telah dikenal pasti 
sebagai statistik peramal bagi kawalan antikoagulan yang baik. Kajian ini 
menjelaskan bahawa pengetahuan pesakit tentang warfarin amat penting,  bukan 
hanya dalam meningkatkan kawalan INR, malahan juga dalam usaha meningkatkan 
QoL pesakit. Intervensi pendidikan yang berterusan adalah disarankan.  
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ASSESSMENT OF MEDICATION ADHERENCE, 
KNOWLEDGE, AND HEALTH-RELATED QUALITY OF LIFE 
AMONG ATRIAL FIBRILLATION PATIENTS USING 
WARFARIN IN PENANG, MALAYSIA 
 
ABSTRACT 
The use of oral anticoagulant therapy (OAC) has been a standard clinical 
practice to prevent stroke in patients with atrial fibrillation. In Malaysia, studies 
evaluating knowledge, non-adherence and quality of life among patients with chronic 
use of warfarin and their relationship with their anticoagulation control, are still 
recent and scarce. 
This PhD study aims to gain insight into the knowledge and adherence of 
atrial fibrillation patients in Penang state towards oral anticoagulant medication, to 
assess their pattern of health-related quality of life (HRQoL) as well as to investigate 
the relationship of the former studied variables with the anticoagulation control as 
measured by the International Normalized Ratio. This study also aims to explore 
other predictive factors that could potentially explain variations in INR values. A 
novel model described predictors of controlled INR values was developed.  
This cross-sectional study was conducted at the Cardiology Clinics at both 
Hospital Pulau Pinang and Seberang Jaya Hospital, in Penang state. To measure 
anticoagulation knowledge, the Oral Anticoagulation Knowledge (OAK) test was 
used. For HRQoL measure, a specific instrument; the Duke Anticoagulant 
Satisfaction Scale (DASS) and a generic instrument; EuroQoL with five-dimension-
three level (EQ-5D-3L) were used. Both OAK and DASS were translated to Malay 
language and tested for their psychometric properties. For adherence assessment, the 
original eight-item Morisky Medication Adherence Scale (MMAS-8) and the 
translated MMAS-BM in Malay language were used. A questionnaire comprised of 
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the socio-demographic and disease characteristics of the participants was also 
delivered in two languages (English and Malay). For patients’ INR control 
assessment, two methods were used; the time in therapeutic range (TTR method) and 
INR stability method. 
Out of a sample of 382 AF patients that met the research criteria, 339 patients 
have completed DASS, EQ-5D and MMAS-8 questionnaires, but only 328 of them 
completed OAK test and entered the final analysis. Among all study participants, the 
mean age ± SD was 60.4±14.5 years.  
The knowledge of the study participants is generally poor with a mean OAK 
score of only 47%±18% with only 9.5% of patients achieved the passing rate of 75%. 
Their deficiency knowledge was mostly about the basic aspect of warfarin (Dietary 
modification, herbal, drug and alcohol interactions with warfarin, missing dose 
management and its consequence, and the interpretation of INR results). The present 
study revealed a positive association between the patients’ warfarin knowledge and 
the anticoagulation control (INR% and TTR%) (P<0.05).  
Only 48.4% (n=164) of patients reported high medication adherence in the 
present study. Non-adherence was highly reported by younger patients, lower 
education level, patients with lower knowledge score, longer duration on warfarin 
therapy and taking a less number of medications. However, only age, medication 
knowledge scores, and AF with comorbidities were predictors of adherence in the 
multivariate analysis. However, there is no significant association between patients’ 
adherence and the anticoagulation control (TTR or INR%). 
The evaluation of AF patients’ QoL showed a positive perception with an 
average DASS score of 70.8 (±19.8) and the EQ-5D average score of 79.8% (±26.3), 
presented a worse evaluation in Mobility and Pain domains. This study highlighted 
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the significant association between the level of anticoagulation control and its 
impacts on the QoL (P<0.05). 
From all factors that had been studied, the multivariate analysis showed that 
only longer duration of using warfarin (2-5 years) and higher warfarin knowledge 
(OAK score ≥ 75%) were identified as statistical predictors of good anticoagulation 
control. Thus promoting warfarin’s knowledge to patients may be helpful not only in 
improving the INR control but also in improving patients’ QoL. Repeated 
educational intervention is highly recommended. 
 
 
 
1 
 
CHAPTER 1 
INTRODUCTION 
 
1.1 Overview and Background of Atrial Fibrillation 
 Atrial fibrillation (AF) is the most common form of cardiac arrhythmia 
(irregular heart beat) (The Task Force for the Management of Atrial Fibrillation of 
the European Society of Cardiology, 2010). AF is defined as “an atrial 
tachyarrhythmia characterized by uncoordinated atrial activation with consequent 
deterioration of atrial mechanical function described by the absence of consistent P 
waves on the electrocardiogram (ECG)” (Bellet, 1971) (Figures 1.1, 1.2 and 1.3).  
 Approximately 90% of AF patients have nonvalvular AF with different risk 
of strokes (Ang et al., 1998). People with nonvalvular AF generally present with 
palpitations, dyspnoea, chest pain, fatigue, dizziness, presyncope and syncope 
(fainting), or in extreme cases loss of consciousness, although approximately 10–
30% of cases may occur asymptomatically (The Task Force for the Management of 
Atrial Fibrillation of the European Society of Cardiology, 2010). 
 AF is classified based on various classification systems such as; the ECG 
pattern, epicardial or endocavitary recordings, mapping of atrial electrical activity or 
clinical feature (ACCF/AHA/HRS Guidelines, 2011). Levy et al. (2003) classified 
AF based on the temporal pattern of the arrhythmia. When a patient had two episodes 
or more, AF is considered as recurrent. These episodes may be paroxysmal if they 
terminated spontaneously in fewer than 7 days, or persistent if the arrhythmia 
requires electrical or pharmacological cardioversion for termination and lasted longer 
than 7 days. Successful termination of AF does not alter the classification of 
persistent AF in these patients. 
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The third type of AF is the long-standing non-self terminating arrhythmia that 
fails to be terminated by cardioversion, or be preceded by recurrent self-terminating 
episodes, this is classified as permanent. 
 
 
 
Figure 1.1 Schematic diagram of normal sinus rhythm of a human heart as seen on 
the ECG (Goldberger, 2012). 
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Figure 1.2 ECG of atrial fibrillation at a rate of 150 (Goldberger, 2012) 
 
 
Figure 1.3 ECG of atrial fibrillation (top) and normal sinus rhythm (bottom). The 
purple arrow indicates a P wave, which is lost in atrial fibrillation (Goldberger, 2012) 
 
1.2 Prevalence of Atrial Fibrillation  
Atrial fibrillation is the most common sustained cardiac arrhythmia and 
currently affects 1–2% of the United States population (Go et al., 2001; Stewart et 
al., 2001).  Nearly three million people in the United States are diagnosed with AF 
(Naccarelli et al., 2009). The rate of AF increases with age, from less than 1% among 
persons aged younger than 60 years, to 5-15% in 80 years (Naccarelli et al., 2009; 
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Heeringa et al., 2006; Miyasaka et a., 2006; Go et al., 2001; Stewart et al., 2001; 
Ryder & Benjamin, 1999; Feinberg et al., 1995; Wolf, Abbott, & Kannel, 1991). The 
median age of patients with nonvalvular AF is 75 years and 84% of patients with 
nonvalvular AF are over 65 years old (Feinberg et al., 1995). With a growing 
geriatric population in the United States, the prevalence of AF is expected to increase 
by 2.5 fold over the next 50 years (Go et al., 2001; Stewart et al., 2001).  
In Malaysia, heart diseases are the leading cause of death in 2011 accounting 
for 25.64 percent of those who died in Ministry of Health (MOH) hospitals in 2010 
(Ministry of Health, 2011).  However, information on prevalence of AF in Malaysia 
is scarce. Data from The Asian Cardiovascular Market Outlook to 2014 (2009) 
estimated the prevalence of AF by 0.4% of the population in the Asia-Pacific with 
the most prevalent in South Korea, Philippines, Malaysia and Indonesia, affecting 
0.7% of the populations. In a Malaysian cohort study conducted in Kuala Lumpur, 
Malaysia, the prevalence of AF was estimated by 2.8% (Freestone et al., 2003). 
Sivanandam and Lim, (2004) estimated the prevalence of AF based on the fact that 
the incidence of AF increases with age and 2.5% of the population of Malaysia are 
above 70 years of age (Rugayah, 1997), therefore approximately 0.25% of the 
population having AF (known that 10 % of the population above 70 years of age are 
in AF). 
 
1.3 Risk Factors of Atrial Fibrillation 
There are many risk factors for developing AF. Conditions associated with 
AF are also markers of cardiovascular risk and/or cardiac damage rather than simply 
causative factors. 
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1.3.1 Ageing  
The prevalence and incidence of AF increased by increasing age, possibly 
through age-dependent loss and isolation of atrial myocardium and associated 
conduction disturbances (ACCF/AHA/HRS Guidelines, 2011). In the Framingham 
study, the development of AF becomes more likely by increasing age with an odds 
ratio (ORs) of 2.1 for men and 2.2 for women, (P <0.0001) (Benjamin et al., 1994).   
 
1.3.2 Hypertension 
Hypertension is a risk factor for the first incident AF and for AF-related 
complications such as stroke and systemic thromboembolism. Hypertension 
increases the risk of having AF by odds ratio 1.5 for men and 1.4 for women 
(Benjamin et al., 1994). 
 
1.3.3 Heart Failure  
Thirty percent (30%) of AF patients have heart failure with New York Heart 
Association (NYHA) classes II–IV (Nabauer et al., 2009; Nieuwallat et al., 2005) 
and 30–40% of heart failure patients are having AF. Heart failure can be a cause of 
the arrhythmia due to increased atrial pressure and volume overload, secondary 
valvular dysfunction, or chronic neurohumoral stimulation (Fuster et al., 2006). 
 
1.3.4  Valvular Heart Disease 
Valvular heart diseases (e.g., mitral valve stenosis and rheumatic valve 
disease) are found in about 30% of AF patients (Nabauer et al., 2009; Nieuwallat et 
al., 2005). AF caused by left atrial (LA) distension is an early manifestation of mitral 
stenosis and/or regurgitation. AF occurs in later stages of aortic valve disease. In the 
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Framingham study valvualr disease associated with increase AF risk with an odds 
ratio of 1.8 for men and 3.4 for women (Benjamin et al., 1994). 
 
1.3.5 Diabetes Mellitus 
Diabetes mellitus is found in 20% of AF patients, and may contribute to 
arterial damage with an odds ratio 1.4 for men and 1.6 for women (Benjamin et al., 
1994). The relative risks (RRs) for stroke mortality and morbidity associated with 
diabetes were 1.8 in men and 2.2 in women after adjusting for the effect of other risk 
factors including age, blood pressure, and excluding persons with personal history of 
heart attack, heart failure, or stroke (Barrett-Connor &  Khaw, 1988). 
 
1.3.6 Coronary Artery Disease (CAD) 
Coronary artery disease (CAD) is also known as coronary heart disease 
(CHD) is common among those with atrial fibrillation. CAD is present in ≥ 20% of 
the AF population (Nabauer et al., 2009; Nieuwallat et al., 2005). In CAD plaque is 
built up inside the coronary arteries that supply the cardiac muscle with blood that is 
rich in oxygen. If the flow of oxygen-rich blood to the heart muscle is reduced or 
blocked over time, CAD can weaken the heart muscle and lead to heart failure and 
arrhythmias.  
 
1.3.7 Dietary and Lifestyle Factors 
Excessive alcohol or caffeine consumption and emotional or physical stress 
are among the most important lifestyle factors that have been associated with AF. As 
a consequence of an excessive intake of alcohol over a relatively short period, AF 
may develop a so-called ‘holiday heart syndrome’ (Ettinger et al., 1978). The 
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proposed mechanism for alcohol-induced AF is that acute consumption of alcohol 
aﬀects catecholamine release, metabolic acidosis, electrolyte disturbances, and 
increased oxidative distress. In the long term, this resulted in cardiomyopathy, 
structural heart disease, metabolic disturbances, and increased sympathetic tone. The 
combination of these eﬀects contributed to the increase in atrial arrhythmias (Balbão, 
de Paola, & Fenelon, 2009). Among a series of younger patients (aged < 65 years) 
with new onset AF, 63% of cases are caused or contributed by alcohol (Lowenstein 
et al., 1983). 
Besides all factors listed above, obesity, thyroid dysfunction 
(hyperthyroidism), cardiomyopathy, myocarditis, pulmonary embolism and chronic 
renal disease may increase the risk of AF. AF is also common after surgery, 
especially cardiothoracic operations such as thoracotomy and coronary artery bypass 
graft (Fuster et al., 2006).  
 
1.4 Prognosis of Atrial Fibrillation 
AF is associated with increased rates of death, hospitalizations, stroke, left 
ventricular dysfunction (LVD) and reduced quality of life and exercise capacity.  
 
1.4.1   Death  
The rate of death is doubled by AF, independently of other known predictors 
of mortality (Kirchhof et al., 2007; Stewart et al., 2002, Wolf et al., 1998). The odds 
ratios for death from AF were estimated at 1.5 for men and 1.9 in women, which 
does not vary by age (Benjamin et al., 1994). 
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1.4.2   Hospitalizations 
AF accounts for one-third of all admissions for cardiac arrhythmias. It is 
expected that the number of hospitalizations associated with AF continues to 
increase, following an already observed 14.4% increase from 1985 to 1999 among 
adults aged 35 years or older (Wattigney, Mensah, & Croft, 2003). 
 
1.4.3   Stroke 
AF patients are with an approximately fivefold greater risk for stroke than 
that of people without AF (Gattellari et al., 2011; Wolf et al., 1998; Wolf et al., 
1991). The incidence of strokes attributable to AF increases from 1.5% at age 50–59 
years to 23.5% at age 80–89 years (Wolf et al., 1991). Stroke in AF has been often 
severe and results in long-term disability or death. Paroxysmal AF carries the same 
stroke risk as permanent or persistent AF. 
 
1.4.4   Left Ventricular Dysfunction (LVD)   
AF is associated with haemodynamic instability with an atrial filling fraction 
less than 40%, this is related to the irregular, fast ventricular rate and increased end-
diastolic LV filling pressure which results in a reduction in cardiac output of up to 
10–20% (Tischler et al., 1990). An uncontrolled AF rate may even precipitate critical 
cardiac ischemia.  
 
1.4.5   Quality of Life and Exercise Capacity 
AF adversely impacts quality of life and overall well-being and it results in 
reduced exercise tolerance. It was found that patients with AF had significantly 
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worse quality of life compared with control subjects with significantly lower total 
functional capacity and global life satisfaction (Sanoski, 2009; Thrall et al., 2006).  
 
1.5 Pathophysiology of Thrombus Formation (Stroke) 
Thrombus associated with AF arises most frequently in the left atrium 
appendage (LAA) which is a muscular pouch connected to the left atrium (LA) of 
the heart. LAA flow velocities are reduced because of loss of organized mechanical 
contraction during AF (Manning et al., 1989). This substrate of decreased flow 
within the LA/LAA has been associated with spontaneous echo contrast, thrombus 
formation, and embolic events (Mitusch et al., 1995). 
 
1.6 Stroke Risk Stratification  
Strokes in patients with AF are more severe than other types of ischaemic 
stroke, and result in greater morbidity and mortality (Gattellari et al., 2011; Béjot et 
al., 2009). The magnitude of the increase in stroke risk in patients with AF depends 
on the presence of other risk factors. Approximately 90% of AF patients have at least 
one or more additional risk factors for stroke (Nieuwlaat et al., 2006). These 
additional risk factors can be used to stratify patients into categories of stroke risk; 
using risk scales such as the CHADS2 score.  
CHADS2 is an acronym derived from the initial letters of Congestive Heart 
Failure, Hypertension, Age, Diabetes, and Stroke (doubled) (Gage et al., 2001). 
CHADS2 is a marker for stroke risk factors and their scoring. CHADS2 is 
calculated by adding 1 point each for any of the following: recent congestive heart 
failure (CHF), hypertension, age 75 years or older, and diabetes mellitus (DM); and 2 
points for a history of stroke or transient ischemic attack (TIA) (Gage et al., 2001).  
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For example, a 78-year-old (+1) patient who had diabetes mellitus (+1) and a prior 
stroke (+2) would have a CHADS2 score of 4. The higher a patient’s CHADS2 score 
indicates a greater risk of stroke (Table 1.1). 
Antithrombotic therapy is highly recommended for patients with AF to 
prevent stroke and transit ischemic attack. Choosing antithrombotic therapy 
(warfarin vs. Aspirin) depends on patients’ CHADS2 score (Fuster et al., 2006). 
 
Table 1.1 Risk of stroke in National Registry of Atrial Fibrillation (NRAF) 
participants, stratified by CHADS2 Score (Adapted with modification from Lip et 
al., 2010; The Task Force for the Management of Atrial Fibrillation of the European 
Society of Cardiology, 2010; Gage et al., 2001). 
 
CHADS2 Score Adjusted stroke rate 
(%/year) 
95% CI (95% confidence 
interval) 
0 1.9  1.2–3.0 
1 2.8  2.0–3.8 
2 4.0  3.1–5.1 
3 5.9  4.6–7.3 
4 8.5  6.3–11.1 
5 12.5  8.2–17.5 
6 18.2 10.5–27.4 
 
 
1.7 Management of Atrial Fibrillation 
The aims of AF treatment are to reduce its symptoms and to prevent severe 
complications associated with AF. These therapeutic goals need to be pursued in 
parallel, especially in the newly detected cases of AF (The Task Force for the 
Management of Atrial Fibrillation of the European Society of Cardiology, 2010). For 
a comprehensive management of AF, it is highly recommended to identify and treat 
the predisposing factors and concomitant disorders (such as hypertension and 
hypercholesterolemia), which increase a patient’s risk of stroke and other 
cardiovascular conditions (Lip, Fat Tse, & Lane, 2012).  
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Thus, the use of antihypertensive including angiotensin converting enzyme 
inhibitors (ACEI) and angiotensin receptor blockers (ARBs), and cholesterol-
lowering therapies such as statins, is highly recommended (Fuster et al., 2006). In 
addition, overall management of AF may involve consideration of three components, 
depending on the subtype of a patient’s AF and/or the severity of their AF-related 
symptoms (Fuster et al., 2006; Lip et al., 2012). 
• Controlling the heart rate: using non-dihydropyridine calcium channel 
blocker (verapamil and diltiazem), beta-blocker (metoprolol, propranolol and 
esmolol) and digoxin. 
• Controlling the heart rhythm using antiarrythmatic agent class Ia (quinidine 
and procainamide), class Ic (propafenone and flecainide) and class III 
(amiodarone, dofetilide, sotalol and ibutilide). 
• Stroke prevention using anticoagulant drug (e.g., warfarin) or antiplatelet 
drugs (e.g., aspirin).  
A management cascade for patients with AF is shown in Figure 1.4. 
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Figure 1.4 Management cascade for patients with atrial fibrillation (AF). ACEI: 
angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; TE: 
thrombo-embolism (Adapted with modification from Lip et al., 2012). 
 
1.7.1 Anticoagulation Therapy  
The use of oral anticoagulant (OAC) therapy has been a standard clinical 
practice to prevent stroke in patients with atrial fibrillation (Ezekowitz et al., 1992; 
Connolly et al., 1991). Coumarins have been used clinically since the 1950s and are 
likely the most widely studied medicines currently in clinical use (Roche-Nagle et 
al., 2003; Link, 1959). The Malaysian statistics on medicine showed that the use of 
warfarin increased in Malaysia, it was used by 0.3946 per 1000 population in 2007 
(Defined Daily Dose (DDD)/1000 inhabitants/day) (Faridah et al., 2010), however, 
in 2008 its usage increased to 0.4753 per 1000 population every day in a year (or a 
DDD/1000 inhabitants/day of 0.4753) (Lian et al., 2013).  
Warfarin is highly effective in reducing the incidence of stroke in patients 
with AF. A meta-analysis demonstrates that adjusted-dose warfarin reduces stroke 
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risk by 64% when compared to placebo, which is corresponding to an absolute 
annual risk reduction in all strokes of 2.7%, while antiplatelet agents reduce stroke 
risk by 22% (Hart, Pearce, & Aguilar, 2007). In the ACTIVE W trial, anticoagulation 
therapy had a relative risk (RR) reduction of 40% when compared to the combination 
of clopidogrel plus aspirin (Connolly et al., 2006). 
Currently, new anticoagulants have been developed include; direct thrombin 
inhibitors (dabigatran etexilate) and factor Xa inhibitors (rivaroxaban and apixaban) 
(Schulman & Majeed, 2012). High cost of dabigatran precludes its use for stroke 
prevention in AF patients in the government hospitals of Malaysia. However, many 
studies found dabigatran was generally cost-effective when assuming the costs 
associated with intracranial haemorrhage, as well as the costs of warfarin monitoring 
and disability following bleeding events (Pharmaceutical Beneﬁts Advisory 
Committee, 2011; Scottish Medicines Consortium, 2011) 
 
1.7.1.1 Warfarin Mechanism of Action 
Warfarin is a drug derived from 4-hydroxycoumarin group; acts by inhibiting 
vitamin K epoxide reductase an enzyme which recycles vitamin K into it reduced 
form (Figure 1.5). Reduced vitamin K is responsible for the carboxylation of the 
specific blood clotting factors II (prothrombin), VII, IX, X as well as anticoagulant 
factor protein C and protein S (Ansell et al., 2008; Malhotra, Nesheim & Mann, 
1985; Friedman et al., 1977). Thus warfarin is not a direct antagonist of vitamin K, 
but rather acts by depletion of reduced vitamin K in tissues which results in a 
reduction in the conversion of fibrinogen to fibrin which in turn reduces clot 
formation (Figure 1.6). 
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Figure 1.5 Mechanism of action of warfarin (Pharmaceutical Information, 2013). 
 
Figure 1.6 Warfarin’s effects on the clotting cascade (Best Practice Journal, 2011). 
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1.7.1.2 Warfarin Pharmacokinetics and Pharmacodynamics 
Warfarin is a racemic mixture of two optically active isomers, the R and S 
enantiomers (Ansell et al., 2008). Warfarin is highly water soluble, rapidly absorbed 
from the gastrointestinal tract, has high bioavailability (Breckenridge, 1978; 
O'Reilly, 1976), and reaches maximal blood concentrations about 1.5 hours after oral 
administration (Kelly & O'Malley, 1979; Breckenridge, 1978). The plasma half life 
of racemic warfarin mixture is 36 to 42 hours (O'Reilly, 1986), this means it takes 
5−7 days to reach steady state since warfarin is started or when the dosage is 
adjusted. 
The antithrombotic effect of vitamin-K anticoagulant has conventionally been 
attributed to their anticoagulant effect, which in turn is mediated by the reduction of 
the four vitamin K-dependent coagulation factors. The vitamin K-dependent clotting 
factors have varying half-lives; 6 hours for factor VII, 24 hours for factor IX, 36 
hours for factor X and 60-72 hours for factor II (prothrombin). Thus, the 
anticoagulant effect develops in two days, whereas an antithrombotic effect of 
warfarin requires six days of treatment (Zivelin, Rao, & Rapaport, 1993). 
Numerous environmental factors such as drugs, diet, and various disease 
states were identified to affect warfarin by altering its kinetics and dynamics 
(Holbrook et al., 2005). For example, drugs such as cholestyramine can reduce the 
absorption of warfarin thus reducing its anticoagulant effect. R-warfarin is 
metabolized primarily by CYP1A2 and CYP3A4, while S-warfarin is metabolized 
primarily by CYP2C9 (Kaminsky & Zhang, 1997). Hence, other potential warfarin-
drug interactions could occur with a concomitant administration of medicines that are 
metabolized by these CYP450s and as a consequence, a number of metabolic 
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medicine interactions have been reported for warfarin. For example, drugs such as 
cimetidine, amiodarone and omeprazole (inhibitors of CYP450); potentiate the 
anticoagulant effect of warfarin by inhibiting its metabolism whereas some drugs like 
barbiturates, rifampin, azathioprine, and carbamazepine (inducers of CYP450); 
inhibit the anticoagulant effect by enhancing its clearance (Orme & Breckenridge, 
1976). In addition, long-term alcohol consumption has a similar potential to increase 
the clearance of warfarin (O'Reilly, 1981). 
Furthermore, aspirin (Dale, Myhre, & Loew, 1980) and non-steroidal anti-
inflammatory drugs (NSAIDs) increase the risk of warfarin-associated bleeding by 
inhibiting platelet function (Battistella, et al., 2005).  
 
1.7.1.3 Dietary Vitamin K  
As the action of warfarin is modified by vitamin K, a variable dietary intake 
of vitamin K may alter the extent of the anticoagulation effect. An increased intake 
of dietary vitamin K (e.g., certain green vegetables or vitamin K-containing 
supplements) will increase the production of vitamin K-dependent coagulation 
factors which is sufficient to reduce the anticoagulant response to warfarin (O’Reilly 
& Rytand, 1980).  Furthermore, patients with poor dietary intake of vitamin K often 
have less stable control of anticoagulation (Sconce et al., 2005). It has been 
suggested to provide these unstable anticoagulated patients with oral vitamin K 
supplementation. However, unrecognized intake of such can lead to warfarin 
resistance (O'Reilly & Rytand, 1980).  
Another consideration should be taken to grapefruit juice. It was found that 
grapefruit juice can enhance the plasma concentration (Cmax) of orally concomitantly 
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administered drugs. This interaction has been reported with 40 pharmaceutical 
products, including the vitamin K antagonist (Saito et al., 2005).  
1.7.1.4 Warfarin Monitoring  
The relation between blood clotting and coumarin derivatives was established 
by Dam and Doisy who shared the Nobel Prize in 1943 for their work 
(MacCorquodale et al., 1939; Dam, 1935). Warfarin has a narrow therapeutic index 
(Katzung, Masters, & Trevor, 2012), which effectiveness and safety is a tight balance 
between stroke risk and bleeding risk, hence a careful dose titration and monitoring 
is required.  
The Prothrombin Time (PT) test is the most common test used to monitor 
vitamin K-anticoagulant therapy (Quick, 1935). The normal prothrombin time is 12-
14 seconds (Hoffbrand, 2002). Since PT monitoring of warfarin treatment is not 
standardized when expressed in seconds, a calibration model which was adopted in 
1982, is now used to standardize PT reporting by converting the PT ratio measured 
with the local thromboplastin into an international normalized ratio (INR) 
(Kirkwood, 1983). INR is calculated by raising the prothrombin time ratio ( the 
patient’s prothrombin time divided by a reference normal prothrombin time) to the 
power of the International Sensitivity Index (ISI) as follow [Equation 1.1] (Dzung et 
al., 1994).   
 
       
             
              
 
   
 
 
Where ISI relates the sensitivity of a given thromboplastin (a tissue factor 
used as a reagent in PT test) to the sensitivity of the World Health Organization’s 
first primary international reference preparation of thromboplastin, which was 
 
 
18 
 
assigned an ISI of 1.0 (Dzung et al., 1994). Each manufacturer assigns an ISI value 
for any tissue factor they manufacture which is usually between 1.0 and 2.0. 
Instead of a specific value of the INR target, a therapeutic window is utilized 
as the recommended target range for specific diagnosis; e.g. in atrial fibrillation the 
clinical benefits of warfarin are highly dependent on maintaining the INR within the 
therapeutic range of between two and three, while mechanical heart valve 
replacement often requires a slightly higher target range of INR (2.5-4.0) (Oake et 
al., 2008; Odén, Fahlén, & Hart, 2006; Hirsh et al., 2001; Hylek et al., 1996). As 
shown in Figure 1.7, INRs below this range increase the risk of stroke, while INR 
values above three or four are associated with increased bleeding rate (Fuster et al., 
2006). 
 
Figure 1.7 Maintaining INR in the therapeutic range is crucial to prevent strokes and 
avoid bleeding (Fuster et al., 2006). 
 
Further quality assessment of the treatment involves calculation of 
Time spent in the Therapeutic Range (TTR) (Rosendaal et al., 1993). In 
Rosendaal method, the difference between 2 consecutive INR readings, 
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which was within the target range, was divided by the total difference 
between them (for more details about Rosendaal method refer to Chapter 3).  
 1.7.1.5 Warfarin Related-adverse Drug Events 
The most common side-effect from over-anticoagulation is bleeding from any 
anatomical site. There are many risk factors that increase the risk of hemorrhage in 
patients on oral anticoagulant therapy, such as increasing age (≥ 60 years), previous 
stroke, diabetes mellitus, recent myocardial infarction, anemia (defined as 
haematocrit < 30%), presence of malignancy, concomitant antiplatelet usage, 
uncontrolled hypertension, liver/renal failure and previous gastrointestinal bleeding 
(Tay, Lane, & Lip, 2008). 
The most feared hemorrhagic complication of anticoagulants is the 
intracranial hemorrhage (ICH) which accounts for approximately 90% of deaths 
from warfarin associated hemorrhage and for the majority of disability among 
survivors (Fang et al., 2007). Nonetheless, ICH rates in clinical trials conducted in 
AF patients on oral anticoagulant therapy are small, reported to be between 0.3% and 
0.6% per year (Hart, Tonarelli, & Pearce, 2005), and the absolute increase in major 
extracranial hemorrhages is even smaller, at ≤ 0.3% per year (Lip & Lim, 2007).  
The risk of ICH associated with warfarin use was twice that of aspirin but the 
absolute risk was small at 0.2% per year (Hart et al., 2007).  
Other than hemorrhage, other important side effects of warfarin are acute 
thrombotic complications, such as dermal vascular necrosis and limb gangrene 
(Weinberget et al., 1983; Verhagen, 1954).   
 
1.8 Medication Knowledge 
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Patient’s knowledge of medication use is of vital importance in the prevention 
of drug related problems and for treatment success as it offers an opportunity for one 
to attain a full health potential. The provision of information required by patients 
relating to their disease and the medication they are to use is not only a necessary 
factor in treatment success but also a right (Brown & Bussell, 2011). Otherwise, 
treatment outcomes will not be achieved if such information is not given in a simple 
clear format that can be understood by the patient.  
Currently, only two valid and reliable anticoagulation knowledge 
questionnaires are available; the Oral Anticoagulation Knowledge (OAK) test, 
created and validated by Zeolla et al. (2006), and the Anticoagulation Knowledge 
Assessment (AKA) questionnaire, designed and validated by Briggs et al. (2005). 
Both have been validated for content validity, construct validity, and reliability.  
 
1.9 Health-Related Quality of Life (HRQoL) 
Quality of life (QoL) is a ubiquitous concept that has different philosophical, 
political and health-related definitions; it includes the physical, functional, emotional 
and social aspects of health. The concept quality of life (QoL) and, more specifically 
health-related quality of life (HRQoL) emerged in the literature in 1920 (Wood-
Dauphinee, 1999) and since then various definitions have been proposed. Cella and 
Nowinski (2002) defined HRQoL as the extent to which one’s physical, emotional 
and social well being are affected by a medical condition or its treatment.  
HRQoL is a subjective construct based on patient-reported outcome from 
their perspective, usually measured with carefully designed and validated 
instruments such as questionnaires or semi-structured interview schedules. It is also 
multidimensional that composed of broad domains to provide both an overall 
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indicator of a person’s HRQoL as well as separate indicators for each domain 
(Taylor, Gibson, & Franck, 2008). 
In relation to specific domains, physical aspect refers to bodily functions that 
may be influenced by disease symptoms and treatment side-effects (e.g., pain, 
nausea, fatigue). Functional well-being represents the ability of the persons to 
perform his/her usual daily activities (e.g., work, study, housework, family leisure 
activities). Social well-being includes social relationships, interaction and support. 
Finally, emotional well-being is ranging from stress and anxiety to a ppositive sense 
of well-being (Cella & Nowinski, 2002). In another word, HRQoL is the assessment 
of physical, functional, emotional and social dimensions of health that are influenced 
by an individual’s perception of his/her health status, the disease and its treatment. 
 
1.9.1 Measurement of HRQoL  
By evolving HRQoL researches, there has been a proliferation of HRQoL 
instruments which can be either generic or disease-specific measures (Solans et al., 
2008). Generic scales assess constructs that are common to a wide range of 
population and patients (e.g., physical function, physical role, bodily pain, general 
health, vitality, social function, emotional role, and mental health). In contrast to 
generic scales, condition specific scales are intended to be much more narrowly 
focused toward those aspects of HRQoL that are of the greatest salience of the 
specific condition (Solans et al., 2008). For example, an arthritis specific scale might 
include questions about joint pain, the number of joints that are swollen or tender, 
and so forth. 
The following are example of generic instrument:   
 Medical Outcome Study Short Form 36 (SF-36) 
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 EuroQol (EQ-5D) 
 Sickness Impact Profile (SIP) 
 Nottingham Health Profile (NHP) 
Disease -specific instruments such as: 
 Functional Assessment Of Cancer Therapy-General (FACT-B) 
 European Organization Of The Research And Treatment Of Cancer 
Quality Of Life Questionnaire Core 30-item (EORTC QLQ-C30) 
 
The most consistently used generic QoL scales in AF studies include the SF-
36, the Short Form-12 (SF-12), and the EuroQOL/EQ-5D. It has been extensively 
validated, has a long track record of use in a variety of medical conditions, and has 
the additional advantage of having a well-accepted method (the EQ-5D) for 
transforming raw scores to preference-based utility weights (Rabin & de Charro, 
2001) 
Strengths of the generic tools for measuring QoL in AF studies include their 
extensive validation, generalizability, and the wealth of data already collected on AF 
patients. The greatest weakness of the generic measures is that, by design, they 
reflect general health and functioning, and, therefore, scores among AF patients are 
strongly influenced by patient demographics and comorbid conditions (Reynolds et 
al., 2006a).  This makes the generic measures potentially less sensitive to change in 
the many older AF patients who have multiple health problems  
 
1.10 Adherence to Medication 
Medication adherence is defined as “the extent to which a patient take 
medication as prescribed by their health care providers” (Osterberg & Blaschke, 
2005). According to the World Health Organization (2003), adherence is defined as 
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“the extent to which a person’s behavior - taking medication, following a diet and/or 
executing lifestyle changes - corresponds with agreed recommendations from the 
health care provider”. Nonadherence includes not only a cessation of medication 
therapy but also taking the medication other than as prescribed (e.g., under 
adherence, over adherence, or not taking the dose at the prescribed time). 
Most studies report the rate of medication adherence as a percentage of doses 
actually taken out of those prescribed medications over a specific period of time 
(Osterberg & Blaschke, 2005; Winkler et al., 2002). Patients with acute conditions 
reported higher adherence rates as compared to those with chronic conditions, whose 
adherence dropped most dramatically after the first six months of therapy (Cramer et 
al., 2003; Haynes, McDonald, & Garg, 2002). It was cited that adherence rates to 
long-term therapy was approximately 50%, regardless of the illness, regimen or 
measurement criteria (DiMatteo, 2004). Other literatures reported that adherence rate 
among patients receiving treatment for chronic conditions, ranged from 43% to 78% 
(Cramer et al., 2003; Claxton, Cramer, & Pierce, 2001). In another systemic review, 
the non-adherence to medication is estimated to affect approximately 30-50% of 
patients with chronic conditions (Haynes et al., 2008). However, there is no 
consensual standard for what constitutes adequate adherence, some trials consider 
rates of greater than 80% to be acceptable, whereas others consider rates of greater 
than 95% to be mandatory for adequate adherence (Osterberg & Blaschke, 2005). 
Nonadherence may be intentional (for example patients decide not to take the 
medication) or unintentional (patients forget or are unable to take their medication) 
(Unni & Farris, 2011). The consequences of non-adherence include a treatment 
failure, poor health outcomes and increased healthcare costs. For example, non-
adherence is responsible for 48% of asthma deaths, an 80% increased risk of death in 
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diabetes and a 3.8-fold increased risk of death in the year following a heart attack 
(Elliot, 2009). In the United Kingdom (UK) the cost of unused or unwanted 
medicines was estimated to exceed £300 million annually (Trueman et al., 2010).  
Two methods often used to evaluate and assess patients’ adherence to 
medication are medication event monitoring systems (MEMS) and self-reported 
questionnaires (SRQs) (Farmer, 1999). The MEMS is a medication vial cap that 
electronically records the date and time of bottle opening. It is also known as the 
“imperfect gold standard,” due to its recording effectiveness in the measurement of 
patient adherence (Claxton et al., 2001). This method has many disadvantages such 
as; it could be time consuming, expensive and may not be suitable for all medications 
or formulations. 
Another method is the self-reported questionnaires (SRQs) which has been 
considered the method of choice for measuring non-adherence in clinical practice 
(National Collaborating Centre for Primary Care, 2009).  SRQs have frequently been 
used because they are low in both cost and time expenditure, relatively unobtrusive, 
can be used on all types of medicines and are able to distinguish between intentional 
and unintentional non-adherence (Garfield et al., 2011). Other research suggested 
that self-reported method may provide a reasonably accurate estimate of adherence 
(Grymonpre et al., 1998; Craig, 1985). 
On the other hand, earlier studies found that the self-reported method was 
underestimating non-adherence when compared with pill counts or biological assays 
(Gordis, Markowitz, & Lilienfeld, 1969; Park & Lipman, 1964). Furthermore, 
another limitation of SRQs use, that they are subjected to measurement bias such as 
social desirability, recall bias, and response bias (Cook et al., 2005; Garber et al., 
2004). 
